Best GLP-1 telehealth programs that work with UnitedHealthcare of 2026

UHC's commercial plans cover Wegovy and Zepbound with PA, but UHC's pharmacy benefit manager (OptumRx) is the strictest in the category. Programs that don't know OptumRx's PA form get denied.

What to know first

UnitedHealthcare commercial plans use OptumRx as the pharmacy benefit manager, and OptumRx's GLP-1 PA review is the most rigorous in the US commercial market in 2026. Patients with UHC EPO and PPO plans need the prescriber to submit the correct comorbidity coding, prior-medication-failure documentation and treatment-plan attestation. Programs that file the standard generic PA template get denied by OptumRx at higher rates than the category average.

What we considered

  • In-network with UHC commercial
  • Knows OptumRx PA-form specifics
  • Handles OptumRx step-therapy correctly
  • Coordinates with UHC's M&R cardiovascular indication for Wegovy when applicable

Some visit links earn us a commission.

Scores out of 10, equal-weighted across five dimensions. How we score

Top pick: Knownwell

Form Health has the highest documented UHC/OptumRx approval rate in the chart, because their obesity-medicine specialists understand exactly which boxes OptumRx wants checked.

Why Knownwell won this category

Form Health wins the UHC category because OptumRx is the hardest PBM to satisfy in the category, and Form Health's obesity-medicine physicians know the specific documentation OptumRx reviewers require. OptumRx's PA form asks for comorbidity ICD-10 codes, prior-medication-failure documentation, a treatment plan attestation, and provider attestation that the drug is medically appropriate under Wegovy's labeled criteria. Generic PA templates from programs without UHC-specific experience miss one or more of these fields, which triggers a denial.

Form Health's program fee is $299/month, with medication billed separately. For UHC patients with approval, all-in costs run roughly $324/month ($299 program fee plus a $25 insurance copay). The math on a first-pass OptumRx approval versus two denial cycles is measured in weeks and hundreds of dollars of prior-program fees paid while waiting.

Who this pick isn't for

Form Health is not the right pick if your UHC plan is an employer-sponsored self-funded plan that excluded the weight-management benefit. UHC sells to large self-funded employers, and the employer chooses the benefit design. Many UHC commercial lives are on plans that exclude anti-obesity medications. Form Health will verify your coverage at intake, but if no benefit exists, the $299/month fee applies for the clinical service with no medication coverage.

PlushCare is the right pick for UHC members whose comorbidity documentation is already complete and who mainly need a prescriber to file the OptumRx form correctly. The per-submission approval rate gap between PlushCare and Form Health narrows substantially when the clinical picture is clean and the documentation is already in hand.

Runner-up: 9amHealth

PlushCare is the right runner-up for UHC members with clean comorbidity documentation who want to minimize the program fee while the PA is pending.

9amHealth logo
9amHealth9amHealth targets metabolic-syndrome patients where UHC coverage is most reliable.
Starts From
$298/moincl. medication
Lock-In
Month-to-month
Score
7.3

Top 3 compared

ProgramScoreStarts fromLock-inTime to Rx
Knownwell6.9$149/moMonth-to-month14 days
9amHealth7.3$298/moMonth-to-month5 days

Other strong picks

9amHealth logo
9amHealth9amHealth targets metabolic-syndrome patients where UHC coverage is most reliable.
Starts From
$298/moincl. medication
Lock-In
Month-to-month
Score
7.3

Frequently asked questions

Does UnitedHealthcare cover Wegovy?
Yes. UHC commercial PPO and EPO plans cover Wegovy (semaglutide 2.4 mg) with prior authorization through OptumRx. The PA criteria require BMI 30 or higher (or BMI 27 with a comorbidity), prior documentation of appropriate diet and exercise, and in many plan designs a step-therapy trial. Coverage depends on whether your employer's specific plan design includes the anti-obesity drug benefit. Self-funded employer plans frequently exclude it.
Why does UHC/OptumRx deny GLP-1 prior authorizations more often?
OptumRx's PA form is more granular than Aetna's or Cigna's. It requires specific ICD-10 comorbidity codes (not just a general BMI note), a formal treatment-plan attestation signed by the prescribing provider, documentation of prior anti-obesity medications tried and failed, and provider attestation of medical appropriateness. Programs that file a generic PA template miss one or more of these requirements, triggering a denial that adds 4 to 8 weeks before a second submission.
Does UHC cover Zepbound?
Yes. UHC commercial plans cover Zepbound (tirzepatide) with prior authorization through OptumRx, on plans that have elected the weight-management benefit. The formulary tier and step-therapy requirements for Zepbound may differ from Wegovy by plan design. Verify Zepbound's specific tier and any step-therapy requirement on your plan's drug list before submitting the PA, because some UHC plan designs require a trial of a semaglutide product before approving tirzepatide.

Prior authorization letter templates

If your plan requires prior authorization, these templates cover the most common GLP-1 indications. Each letter is pre-filled with the correct ICD-10 codes, clinical criteria, and supporting trial citations for this insurer.

See all PA letter templates →

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.